# International Flavors & Fragrances (IFF) Financial Model Free Excel 3-statement financial model and company analysis for International Flavors & Fragrances. - Canonical: https://finamodel.com/companies/international-flavors-fragrances - Industry: Chemicals - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/IFF.xlsx ## Model Purpose This model provides a comprehensive equity valuation and credit analysis platform for International Flavors & Fragrances (IFF), enabling analysts to forecast the company's deleveraging trajectory and margin recovery following the transformational divestiture of its Pharma Solutions business and the 2025 restructuring of its Nourish segment. ## Company Overview International Flavors & Fragrances (IFF) is a global leader in the creation of value-added ingredients for the food, beverage, health, biosciences, and scent markets. The company leverages deep R&D capabilities to produce proprietary formulations that serve as critical, low-cost components in consumer packaged goods. Business segments (based on 2024 reporting): * **Nourish (~51% of revenue):** Provides flavour compounds and functional food ingredients. * **Scent (~21% of revenue):** Creates fragrance compounds for fine perfumes and consumer products. * **Health & Biosciences (~19% of revenue):** Develops enzymes, cultures, and probiotics for dietary supplements and industrial uses. * **Pharma Solutions (~9% of revenue):** Produces pharmaceutical excipients (divested to Roquette in May 2025). The United States accounts for approximately 28% of sales, with the remainder highly diversified globally. IFF operates a B2B, asset-moderate business model characterised by high R&D intensity, sticky customer relationships, and significant pricing power. The company competes in a consolidated oligopoly alongside Givaudan, Symrise, and dsm-firmenich. Recently, IFF has focused on aggressive deleveraging following its debt-heavy 2021 merger with DuPont's Nutrition & Biosciences division, culminating in the $2.85 billion sale of Pharma Solutions and the restructuring of the Nourish segment into "Taste" and "Food Ingredients" effective January 2025. ## Revenue Deep Dive ### Nourish * **Segment name:** Nourish (Note: Restructured into Taste and Food Ingredients in 2025) * **Revenue driver formula:** Prior Year Revenue x (1 + Volume Growth + Price/Mix Impact) * **Historical growth rate:** Flat to 4% currency-neutral growth. * **Key growth levers and headwinds:** Strong demand in core flavours offset by recent volume softness and pricing pressure in functional ingredients. * **Pricing dynamics:** Value-based pricing with raw material cost pass-through mechanisms. * **Revenue recognition notes:** Recognised at a point in time upon shipment or delivery. * **Seasonality:** Mildly stronger in the first half of the year as consumer packaged goods customers build inventory for summer beverage and food consumption. ### Scent * **Segment name:** Scent * **Revenue driver formula:** Prior Year Revenue x (1 + Fine Fragrance Growth + Consumer Fragrance Growth) * **Historical growth rate:** 5% to 12% currency-neutral growth. * **Key growth levers and headwinds:** Premiumisation in fine fragrances and strong volume recovery in consumer goods. * **Pricing dynamics:** Highly contractual, with long-term briefs won from major consumer goods companies. * **Revenue recognition notes:** Point in time upon transfer of control. * **Seasonality:** Stronger in Q3 and Q4 ahead of the holiday gifting season for fine fragrances. ### Health & Biosciences * **Segment name:** Health & Biosciences * **Revenue driver formula:** Prior Year Revenue x (1 + Volume Growth + Price/Mix Impact) * **Historical growth rate:** 6% to 8% currency-neutral growth. * **Key growth levers and headwinds:** Structural growth in probiotics, cultures, and animal nutrition, driven by global health and wellness trends. * **Pricing dynamics:** High pricing power due to the proprietary, patent-protected nature of biological cultures. * **Revenue recognition notes:** Point in time upon transfer of control. * **Seasonality:** Generally consistent throughout the year. ### Pharma Solutions (Discontinued Operations) * **Segment name:** Pharma Solutions * **Revenue driver formula:** Stub period revenue (January to May 2025) prior to divestiture close. * **Historical growth rate:** ~10% to 12% prior to sale. * **Key growth levers and headwinds:** Divested to Roquette; model must handle the removal of this revenue stream post-Q2 2025. ## Cost Structure ### Variable Costs / COGS * **Line-by-line breakdown:** Raw materials (natural extracts, synthetic chemicals, agricultural commodities), direct manufacturing labour, plant overhead, and inbound freight. * **Gross margin range:** 32% to 36% (improving recently due to productivity gains and volume leverage). * **Key input costs and commodity exposures:** Citrus oils, petrochemical derivatives, soy, and energy costs. * **How COGS scales with revenue:** Largely linear, though gross margins expand during periods of high volume growth due to fixed manufacturing overhead absorption. ### Operating Expenses * **R&D:** Approximately 4.5% to 5.0% of revenue. Crucial for maintaining the product pipeline and winning new customer briefs. Mostly expensed as incurred. * **SG&A:** Approximately 15% to 17% of revenue. Driven by global sales force headcount, marketing, and corporate administrative costs. * **Depreciation & Amortisation:** Exceptionally high (often 8% to 10% of revenue) due to the massive intangible asset base created by the DuPont N&B and Frutarom acquisitions. * **Restructuring / one-time charges:** Frequent and material. The company regularly reports restructuring charges and significant goodwill impairments (e.g., $1.15 billion impairment in 2025). ### Margin Profile * **Gross margin:** 32% to 36%. * **Adjusted Operating EBITDA margin:** 18% to 20% consolidated. Segment margins vary widely: Health & Biosciences (~30%), Scent (~21%), Nourish (~14%). * **Margin trend:** Expanding. The company is realising productivity gains and shedding lower-margin businesses to improve the consolidated profile. ## Balance Sheet Structure * **Total assets:** Approximately $30 billion to $35 billion, heavily skewed toward intangibles. * **Key asset categories:** Goodwill and intangible assets make up over 60% of total assets, a legacy of transformational M&A. * **Working capital profile:** * **Days Sales Outstanding (DSO):** 55 to 65 days. * **Days Inventory Outstanding (DIO):** 100 to 120 days. High inventory is required to secure natural raw materials that have single annual harvest cycles. * **Days Payable Outstanding (DPO):** 60 to 75 days. * **Net working capital as % of revenue:** 20% to 25%. * **Working capital dynamic:** Positive working capital. Growth consumes cash due to the heavy inventory requirements of the natural ingredients supply chain. * **PP&E:** Represents global manufacturing and R&D facilities. Useful lives range from 10 to 40 years for buildings and 3 to 20 years for machinery. ## Capital Expenditure & Investment * **Capex as % of revenue:** 4.0% to 5.0%. * **Maintenance capex vs. growth capex:** Approximately 50% maintenance, 50% growth (capacity expansion for biosciences and flavours). * **Major capex programmes:** Expanding Latin American footprint (e.g., new enzyme hub and application labs in Brazil). * **M&A pattern:** Historically a transformational acquirer (DuPont N&B, Frutarom). Currently in a strict divestiture phase (Pharma Solutions, Savory Solutions, Cosmetic Ingredients) to repair the balance sheet. ## Debt & Capital Structure * **Total debt:** Gross debt was ~$10 billion at the end of 2024, reduced dramatically to ~$4.7 billion by Q3 2025 following the Pharma Solutions divestiture proceeds. * **Debt/EBITDA ratio:** Target is Net Debt to Credit-Adjusted EBITDA below 3.0x (achieved in mid-2025). * **Credit rating:** Investment grade (BBB- / Baa3), which the company is highly focused on defending. * **Key debt instruments:** Senior unsecured notes, term loans, and a revolving credit facility. * **Interest rate profile:** Predominantly fixed-rate bonds, with a weighted average cost of debt around 4.5% to 5.5%. * **Share repurchase programme:** Suspended. Capital allocation is entirely focused on debt reduction. * **Dividend policy:** The dividend was halved in 2024 to $1.60 per share annually to preserve cash for deleveraging. ## Cash Flow Characteristics * **Operating cash flow conversion:** OCF is typically $1.0 billion to $1.3 billion annually. * **Free cash flow margin:** 5% to 8% of revenue. * **Major non-cash items:** Massive D&A add-backs, frequent goodwill impairments, and deferred taxes. * **Working capital cash flow impact:** Inventory builds often act as a significant use of cash during inflationary periods or supply chain disruptions. * **Cash tax rate:** Typically lower than the statutory rate due to global tax planning and the amortisation of tax-deductible goodwill in certain jurisdictions. ## Sheet Structure 1. **Assumptions:** Hardcoded drivers for macro variables, segment growth rates, margin targets, working capital days, and WACC. 2. **Revenue Build:** Segment-level forecasting for Nourish, Scent, Health & Biosciences, and a stub-period calculation for Pharma Solutions. 3. **Income Statement:** GAAP and Non-GAAP (Adjusted Operating EBITDA) views, explicitly separating out amortisation of acquisition-related intangibles and restructuring charges. 4. **Balance Sheet:** Standard asset, liability, and equity line items, with a detailed breakout of Goodwill and Intangible Assets. 5. **Cash Flow Statement:** Indirect method starting from Net Income, highlighting the massive D&A add-back and the cash proceeds from the 2025 divestitures. 6. **Debt Schedule:** Tranche-by-tranche debt build, calculating interest expense and modelling the massive 2025 principal paydowns using divestiture proceeds. 7. **Working Capital:** Schedules for Accounts Receivable, Inventory, and Accounts Payable driven by DSO, DIO, and DPO. 8. **Depreciation & Amortisation:** Waterfall schedules for PP&E capex and the run-off of acquisition-related intangible assets. 9. **DCF Valuation:** Unlevered free cash flow build, WACC calculation, terminal value, and implied share price. ## Key Financial Relationships 1. `Nourish Revenue = Prior Year Nourish Revenue * (1 + Nourish Volume Growth + Nourish Price/Mix)` 2. `Scent Revenue = Prior Year Scent Revenue * (1 + Scent Volume Growth + Scent Price/Mix)` 3. `Health & Biosciences Revenue = Prior Year H&B Revenue * (1 + H&B Volume Growth + H&B Price/Mix)` 4. `Pharma Solutions Revenue = IF(Year=2025, 2024 Revenue * (5/12) * (1 + Growth Rate), 0)` 5. `Consolidated Adjusted Operating EBITDA = Sum(Segment Adjusted Operating EBITDA) - Unallocated Corporate Expenses` 6. `Segment Adjusted Operating EBITDA = Segment Revenue * Segment Adjusted EBITDA Margin` 7. `Gross Profit = Total Revenue - (Total Revenue * COGS %)` 8. `Amortisation of Intangibles = Prior Year Intangibles Balance * Blended Amortisation Rate` 9. `Interest Expense = Average Total Debt * Weighted Average Interest Rate` 10. `Accounts Receivable = (Total Revenue / 365) * DSO` 11. `Inventory = (COGS / 365) * DIO` 12. `Accounts Payable = (COGS / 365) * DPO` 13. `Free Cash Flow = Cash Flow from Operations - Capital Expenditures` 14. `Net Debt = Total Short-Term Debt + Total Long-Term Debt - Cash and Cash Equivalents` 15. `Leverage Ratio = Net Debt / Consolidated Adjusted Operating EBITDA` ## Cross-Sheet Dependencies * The **Assumptions** sheet dictates the growth and margin profiles on the **Revenue Build** and **Income Statement**. * The **Income Statement** generates Net Income, which is the starting point for the **Cash Flow Statement**. * The **Cash Flow Statement** calculates the change in cash and debt paydowns, which feed the **Balance Sheet** and **Debt Schedule**. * The **Debt Schedule** calculates Interest Expense, which flows back to the **Income Statement**. This creates a circular reference that must be managed with a toggle switch. * The **Working Capital** sheet uses Revenue and COGS from the **Income Statement** to calculate balance sheet accounts, and the period-over-period changes flow to the **Cash Flow Statement**. ## Sign Convention * **Revenue and Assets:** Entered and displayed as positive numbers. * **Expenses (COGS, SG&A, Interest):** Entered as positive numbers in their specific build schedules, but subtracted in aggregation formulas (e.g., Gross Profit = Revenue - COGS). * **Liabilities and Equity:** Entered and displayed as positive numbers. * **Cash Flow Statement:** Cash inflows (e.g., Net Income, D&A, Divestiture Proceeds) are positive. Cash outflows (e.g., Capex, Dividends, Debt Repayment, Working Capital increases) are negative. ## Things Most Likely to Go Wrong * **Pharma Solutions Divestiture Timing:** The $2.85 billion sale to Roquette closed in May 2025. The model must accurately reflect a 5-month stub period for revenue and EBITDA in 2025, and inject the ~$2.6 billion net cash proceeds into the cash flow statement to pay down debt. * **Nourish Segment Restructuring:** IFF reorganised Nourish into "Taste" and "Food Ingredients" in 2025. If modelling historicals, the builder must ensure apples-to-apples comparisons or clearly note the pro-forma mapping. * **GAAP vs. Non-GAAP Distortions:** IFF's GAAP earnings are heavily distorted by massive intangible amortisation and frequent goodwill impairments (e.g., $1.15 billion in 2025). The model must explicitly build to Adjusted Operating EBITDA to reflect true cash-generating capacity. * **Working Capital Drag:** IFF requires high inventory levels (DIO > 100 days). Failing to model the cash drag of inventory builds during growth phases will overstate Free Cash Flow. * **Interest Expense Circularity:** The massive debt paydown in 2025 drastically reduces interest expense. The model must accurately average the debt balance in 2025 to avoid overstating interest costs. * **Dividend Policy:** The dividend was cut to $1.60 per share in 2024. Projecting historical dividend growth rates will drain cash incorrectly; the model must hardcode the new, lower dividend policy. * **Assets Held for Sale:** Divested entities (like Soy Crush) are often moved to "Assets Held for Sale" on the balance sheet prior to closing, which can confuse historical working capital calculations. ## Validation Checks * "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period." * "Net Debt to Adjusted Operating EBITDA should drop below 3.0x by the end of 2025 due to the Pharma Solutions divestiture proceeds." * "Consolidated Adjusted Operating EBITDA margin should remain between 18.0% and 21.0%." * "Capex as a percentage of revenue should remain between 4.0% and 5.0%." * "Days Inventory Outstanding (DIO) should remain above 100 days; flag if it drops below 90 days as this is unrealistic for their supply chain." * "Total Revenue in 2025 should show a YoY decline due to the removal of Pharma Solutions, despite underlying organic growth in core segments." * "Dividend payout should equal exactly $1.60 per share multiplied by the outstanding share count." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Nourish Organic Growth | 3.5 | % | Mid-point of recent historical currency-neutral growth and recovery in flavours. | | Scent Organic Growth | 7.0 | % | Continued strong momentum in fine fragrances and consumer goods. | | Health & Biosciences Growth | 6.5 | % | Structural tailwinds in probiotics and enzymes. | | Nourish Adj. EBITDA Margin | 14.5 | % | Slight expansion from 2024 levels due to productivity initiatives. | | Scent Adj. EBITDA Margin | 21.5 | % | Stable margin profile based on 2024 actuals. | | H&B Adj. EBITDA Margin | 30.0 | % | High-margin proprietary biological products. | | SG&A as % of Revenue | 16.0 | % | Historical average, reflecting global sales and administrative footprint. | | R&D as % of Revenue | 4.5 | % | Required investment to maintain innovation pipeline. | | Days Sales Outstanding (DSO) | 60 | Days | Based on historical receivables relative to revenue. | | Days Inventory Outstanding (DIO) | 110 | Days | High inventory requirement for natural raw materials. | | Days Payable Outstanding (DPO) | 65 | Days | Based on historical payable trends. | | Capex as % of Revenue | 4.5 | % | Management guidance for maintenance and growth investments. | | Effective Tax Rate | 20.0 | % | Adjusted effective tax rate excluding one-time impairment impacts. | | Annual Dividend per Share | 1.60 | $ | Hardcoded based on the 2024 dividend cut announcement. | | Weighted Average Cost of Debt | 5.0 | % | Blended rate of outstanding senior notes and term loans. | | WACC | 8.5 | % | Standard discount rate for specialty chemical peers. | | Terminal Growth Rate | 2.0 | % | Long-term GDP-aligned growth for consumer staple inputs. | ## Data Sources & Benchmarks * **Filings:** SEC EDGAR (IFF 10-K, 10-Q, and 8-K filings), IFF Investor Relations website. * **Key Peers:** Givaudan (GIVN.SW), Symrise (SY1.DE), dsm-firmenich (DSFIR.AS). * **Industry Data:** Consumer Packaged Goods (CPG) volume trends, global agricultural commodity pricing (for raw material input costs). * **Consensus Estimates:** Bloomberg or FactSet for forward-looking segment revenue and EBITDA margins. ## Sources * IFF 2024 Form 10-K and Q4 2024 Earnings Release (February 2025). * IFF Q3 2025 Form 10-Q and Earnings Release (November 2025). * Press Release: IFF Announces Sale of its Pharma Solutions Business to Roquette (March 2024). * Press Release: IFF Completes Divestiture of Pharma Solutions Business Unit (May 2025). --- ## Frequently asked questions ### What does International Flavors & Fragrances (IFF) do? International Flavors & Fragrances (IFF) is a global leader specializing in the creation of value-added ingredients for various markets, including food, beverage, health, biosciences, and scent. The company develops proprietary formulations that serve as essential, low-cost components in consumer packaged goods. ### What are the primary revenue drivers for International Flavors & Fragrances? IFF's revenue is primarily driven by its Nourish segment, which accounts for approximately 51% of revenue, followed by Scent at 21% and Health & Biosciences at 19%. The company operates a B2B model characterized by high R&D intensity, sticky customer relationships, and significant pricing power across its globally diversified sales. ### What is the assumed capital expenditure as a percentage of revenue in the IFF financial model? The financial model for International Flavors & Fragrances assumes capital expenditure as a percentage of revenue to be approximately 4.03%. This Capex is roughly split 50% for maintenance and 50% for growth, particularly focusing on capacity expansion in biosciences and flavors. ### What is the projected revenue growth rate used in the International Flavors & Fragrances financial model? The International Flavors & Fragrances financial model incorporates a projected revenue growth rate of 20%. This assumption is crucial for forecasting the company's future financial performance and its path to deleveraging and margin recovery. ### What is the main purpose of the International Flavors & Fragrances financial model? The primary purpose of this financial model is to provide a comprehensive platform for equity valuation and credit analysis of International Flavors & Fragrances. It enables analysts to forecast the company's deleveraging trajectory and margin recovery following significant business changes like divestitures and restructuring. ### Is an Excel model available for International Flavors & Fragrances, and what is its forecast horizon? Yes, a downloadable Excel model is available for International Flavors & Fragrances. This model provides a forecast horizon spanning from fiscal year 2026 through fiscal year 2030, offering detailed projections for future analysis. [Interactive forecast calculator](https://finamodel.com/companies/international-flavors-fragrances/forecast)